These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38606931)

  • 1. Reductions in World Health Organization risk drinking level are associated with improvements in sleep problems among individuals with alcohol use disorder.
    Garcia CC; Richards DK; Tuchman FR; Hallgren KA; Kranzler HR; Aubin HJ; O'Malley SS; Mann K; Aldridge A; Hoffman M; Anton RF; Witkiewitz K
    Alcohol Alcohol; 2024 Mar; 59(3):. PubMed ID: 38606931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reductions in World Health Organization Risk Drinking Level Are Associated With Reductions in Alcohol Use Disorder Diagnosis and Criteria: Evidence From an Alcohol Pharmacotherapy Trial.
    Richards DK; Tuchman FR; Hallgren KA; Kranzler HR; Aubin HJ; O'Malley SS; Mann K; Aldridge A; Anton RF; Witkiewitz K
    J Addict Med; 2024 Apr; ():. PubMed ID: 38606854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial.
    Witkiewitz K; Falk DE; Litten RZ; Hasin DS; Kranzler HR; Mann KF; O'Malley SS; Anton RF
    Alcohol Clin Exp Res; 2019 May; 43(5):979-987. PubMed ID: 30951210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom.
    Witkiewitz K; Heather N; Falk DE; Litten RZ; Hasin DS; Kranzler HR; Mann KF; O'Malley SS; Anton RF
    Addiction; 2020 Sep; 115(9):1668-1680. PubMed ID: 32056311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder.
    Witkiewitz K; Kranzler HR; Hallgren KA; O'Malley SS; Falk DE; Litten RZ; Hasin DS; Mann KF; Anton RF
    Alcohol Clin Exp Res; 2018 Dec; 42(12):2453-2465. PubMed ID: 30395350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels.
    Witkiewitz K; Hallgren KA; Kranzler HR; Mann KF; Hasin DS; Falk DE; Litten RZ; O'Malley SS; Anton RF
    Alcohol Clin Exp Res; 2017 Jan; 41(1):179-186. PubMed ID: 28019652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of Drinking Reductions and Long-term Functioning Among Patients with Alcohol Use Disorder.
    Witkiewitz K; Kranzler HR; Hallgren KA; Hasin DS; Aldridge AP; Zarkin GA; Mann KF; O'Malley SS; Anton RF
    J Gen Intern Med; 2021 Feb; 36(2):404-412. PubMed ID: 33180306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stability of Posttreatment Reductions in World Health Organization (WHO) Drinking Risk Levels and Posttreatment Functioning in Older Adults with DSM-5 Alcohol Use Disorder: Secondary Data Analysis of the Elderly Study.
    Mejldal A; Andersen K; Behrendt S; Bilberg R; Bogenschutz M; Braun-Michl B; Bühringer G; Søgaard Nielsen A
    Alcohol Clin Exp Res; 2021 Mar; 45(3):638-649. PubMed ID: 33496964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety.
    Falk DE; Ryan ML; Fertig JB; Devine EG; Cruz R; Brown ES; Burns H; Salloum IM; Newport DJ; Mendelson J; Galloway G; Kampman K; Brooks C; Green AI; Brunette MF; Rosenthal RN; Dunn KE; Strain EC; Ray L; Shoptaw S; Ait-Daoud Tiouririne N; Gunderson EW; Ransom J; Scott C; Leggio L; Caras S; Mason BJ; Litten RZ;
    Alcohol Clin Exp Res; 2019 Jan; 43(1):158-169. PubMed ID: 30403402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination treatment with varenicline and naltrexone reduces World Health Organization risk drinking levels.
    Nieto SJ; Enders CK; Witkiewitz K; O'Malley SS; Ray LA
    Alcohol Clin Exp Res; 2022 Dec; 46(12):2258-2266. PubMed ID: 36515648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. World Health Organization (WHO) risk level reductions in inpatients with alcohol use disorder and comorbid anxiety disorders.
    Stevenson BL; Anker J; Thuras P; Rinehart L; Kushner MG
    Psychol Addict Behav; 2023 Aug; 37(5):713-722. PubMed ID: 36480397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial.
    Collins SE; Duncan MH; Saxon AJ; Taylor EM; Mayberry N; Merrill JO; Hoffmann GE; Clifasefi SL; Ries RK
    Lancet Psychiatry; 2021 Apr; 8(4):287-300. PubMed ID: 33713622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial.
    Anton RF; Latham P; Voronin K; Book S; Hoffman M; Prisciandaro J; Bristol E
    JAMA Intern Med; 2020 May; 180(5):728-736. PubMed ID: 32150232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of abstinence, no heavy drinking days, and a 2-level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study.
    Wallach JD; Gueorguieva R; Phan H; Witkiewitz K; Wu R; O'Malley SS
    Alcohol Clin Exp Res; 2022 Jul; 46(7):1331-1339. PubMed ID: 35616436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reductions in WHO risk drinking levels correlate with alcohol craving among individuals with alcohol use disorder.
    Tuchman FR; Hallgren KA; Richards DK; Aldridge A; Anton RF; Aubin HJ; Kranzler HR; Mann K; O'Malley SS; Witkiewitz K
    Alcohol Clin Exp Res (Hoboken); 2024 Feb; 48(2):420-429. PubMed ID: 38149364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
    Falk DE; O'Malley SS; Witkiewitz K; Anton RF; Litten RZ; Slater M; Kranzler HR; Mann KF; Hasin DS; Johnson B; Meulien D; Ryan M; Fertig J;
    JAMA Psychiatry; 2019 Apr; 76(4):374-381. PubMed ID: 30865232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. World Health Organization risk drinking levels as a treatment outcome measure in topiramate trials.
    Hartwell EE; Feinn R; Witkiewitz K; Pond T; Kranzler HR
    Alcohol Clin Exp Res; 2021 Aug; 45(8):1664-1671. PubMed ID: 34120366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of sleep quality on lapse to alcohol use during a quit attempt.
    Baskerville WA; Grodin EN; Ray LA
    Alcohol Alcohol; 2024 Jan; 59(2):. PubMed ID: 38366914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Relationship Between Reductions in WHO Risk Drinking Levels During Treatment and Subsequent Healthcare Costs for the ACTIVE Workgroup.
    Aldridge AP; Zarkin GA; Dowd WN; Witkiewitz K; Hasin DS; O'Malley SS; Isenberg K; Anton RF
    J Addict Med; 2022 Jul-Aug 01; 16(4):425-432. PubMed ID: 34864785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baclofen for alcohol use disorder.
    Minozzi S; Saulle R; Rösner S
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012557. PubMed ID: 30484285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.